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Differentiated thyroid cancer is the most common endocrine
malignancy (Simpson et al, 1987) and being diagnosed with
increasing frequency in the USA (Parker et al, 1997). Despite
advances in the treatment of thyroid cancer, disease recurrence and
metastasis may occur in as many as 20% of patients (Loh et al,
1997) and so continue to pose major problems in clinical
management.
Before metastasis in a distant site can develop, tumour cells
must circulate in the peripheral blood or lymphatic channels.
Although the relationship between circulating tumour cells and
the development of secondary disease is not fully understood
(Johnson et al, 1995), a method to detect small numbers of such
cells may provide a tool for the early diagnosis of tumour metas-
tases to better define prognostic groups (Schlumberger et al, 1986;
Sanders and Cady, 1998). This is of particular interest, because
the presence of metastases is an important prognostic indicator
(Simpson et al, 1987; Bellantone et al, 1998) and effective
treatment modalities are available (Noguchi et al, 1998). Reverse
transcription polymerase chain reaction (RT-PCR) is a highly
sensitive technique to detect tissue-specific messenger ribonucleic
acid (mRNA) expression. This approach has already been used
to identify micro-metastases of different solid tumours such as
prostate cancer (Ghossein et al, 1995) and neuroblastoma
(Mattano et al, 1992). RT-PCR is also discussed as a new diag-
nostic tool with increasing popularity for the clinical monitoring of
thyroid cancer patients (Haber, 1998). Controversial results were
published by several groups during the last years and no standard-
ized protocol is established to date (Ditkoff et al, 1996; Tallini
et al, 1998; Ringel et al, 1998). To further define the applicability
and value of this method we amplified thyroglobulin (TG) mRNA
transcripts from peripheral blood samples of 150 patients diag-
nosed with thyroid cancer, 85 patients with non-malignant thyroid
disease and 50 control subjects without evidence or history of
thyroid disease. All experiments were performed using two
different RT-PCR sensitivities. We report here that the detection of
TG mRNA-producing cells in the peripheral blood and the correla-
tion with extrathyroidal disease is crucially dependent on the used
RT-PCR assay sensitivity. In addition, we report that tissue
specific detection of thyroglobulin mRNA expression in different
human tissues is also dependent on assay sensitivity. However,
using our normal assay sensitivity it is possible to correlate the
RT-PCR results with the diagnosis of metastasized thyroid cancer.
METHODS
Patients
After approval by the human study committee, 150 patients with
thyroid cancer (137 without current metastasis, 13 with metas-
tasis), 29 patients with goitre, 56 patients with autoimmune
disease of the thyroid (Graves’ disease, Hashimoto thyroiditis) and
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50 control subjects without evidence or history of thyroid disease,
were studied. Diagnosis of cancer was based on histological exam-
ination of the surgical specimen, diagnosis of autoimmune disease
was based on ultrasound examination and the presence of corre-
sponding antibodies. Diagnosis of goitre as well as of healthy
individuals was based on an appropriate ultrasound examination
and normal serum markers (thyroid-stimulating hormone (TSH),
total thyroxin (T4) and triiodothyronine (T3)). All patients with a
diagnosis of thyroid cancer had been treated and were followed in
the Department of Nuclear Medicine at the Johann Wolfgang
Goethe-University Hospital and volunteered to participate in the
study. After initial treatment with total thyroidectomy, we use a
modification of the protocol described by Schlumberger (1998) in
the follow-up of patients with thyroid cancer.
Blood samples and RNA extraction
The interval between surgery and collecting of blood samples was
> 3 months in all patients, all patients had received one cycle of
radioiodine minimum and were taking L-T4. If there were thyroid
residues detectable by radioscanning or the tumour was > pT2, an
additional cycle of radioiodine was performed within 6 months.
Approximately 9 ml venous blood was obtained from each patient
in the morning prior to any diagnostic procedure in our outpatient
clinic at a routine appointment. Blood samples were immediately
mixed with EDTA to prevent coagulation and cooled to 4°C.
Nucleated cells were isolated using a Percoll gradient (Pharmacia,
Uppsala, Sweden) at a density of 1.09 g ml–1 within 2 h after with-
drawal of blood. Serum for thyroglobulin measurements was
obtained using the supernatant after centrifugation and serum
thyroglobulin was determined with a commercial immunometric
assay (DYNOtest, Brahms Diagnostica, Berlin, Germany). A
serum thyroglobulin level ³ 5 ng ml–1 (on L-T4 therapy) was
considered elevated. The cell suspension was washed once in
0.9% sodium chloride and remaining erythrocytes were lysed.
Total cellular RNA was extracted using RNeasy blood kit (Qiagen,
Hilden, Germany) according to the suggestions of the manufac-
turer and RNA was resuspended in 50 ml RNase-free water.
Optical transmission of the final RNA-preparation was determined
three times at 260 nm using a Gene-Quant calculator (Pharmacia
Biotech, Freiburg, Germany) and the concentration was calcu-
lated. The RNA suspension was directly used for RT-PCR or
immediately stored in liquid nitrogen until use.
Oligonucleotide primers and probes
Thyroglobulin primers were custom designed according to the
human thyroglobulin cDNA sequence reported by Malthiery and
Lissitzky (1987) (Gene Bank accession number U93033). All
primers were synthesized and purified by MWG-Biotech
(Ebersberg, Germany). These primers bind exon 9 and 10 respec-
tively and span a genomic DNA length of 411 kb so that cDNA
and contaminating genomic DNA amplification products can be
distinguished by size (219 bp vs 630 bp). To assess the intactness
of amplifiable RNA two intron-spanning glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) primers that generate a
300 bp fragment (Gene Bank accession number M33197) were
used. The specificity of the primer sets for thyroglobulin and
glyceraldehyde-3-phosphate-dehydrogenase, respectively, was
verified by basic local alignment search tool (BLAST) computer
search (Altschul et al, 1990). The sequences of these PCR primers
are listed in Table 1.
Reverse transcriptase-polymerase chain reaction
Approximately 1.5 mg of total RNA was reverse transcribed in a
final volume of 20 ml containing 4 ml 5 ´ buffer (250 mM Tris-
HCl pH 7.5, 375 mM KCl, 15 mM MgCl2, 50 mM DTT), 20 units
recombinant RNase inhibitor (Promega, Madison, WI, USA),
0.5 mM dNTP, 2.5 mM oligo dT and 200 units RNase H minus
M-MLV reverse transcriptase (Promega). The following PCR was
performed in a total volume of 50 ml containing 3 ml of the
RT-solution, 5 ml 10 ´ reaction buffer (200 mM Tris-HCl pH 8.4,
500 mM KCl), 0.5 mM forward and reverse primer, 0.2 mM of
each dNTP, 2.5 units Taq-DNA polymerase and 1.5 mM MgCl2
(Life Technology, Paisley, Scotland) using a tube-controlled DNA
thermal cycler (AGS-Hybaid, Heidelberg, Germany). Samples
were subjected to 3 min of denaturation at 94°C followed by 30
and 40 cycles respectively (normal and high RT-PCR sensitivity)
of 45 s at 94°C, 30 s at 55°C and 1 min 30 s at 72°C, followed by
additional 10 min at 72°C. In each experiment water was used as a
negative control.
Analysis of amplified thyroglobulin cDNA
10 ml PCR product was mixed with 2 ml 6 ´ loading dye (MBI
Fermentas, Vilnius, Lithuania) and run for 60 min on a 1.5%
agarose gel in TBE buffer (0.1 M Tris pH 8.4, 90 mM boric acid,
1 mM EDTA). The gel was stained with ethidium bromide and the
bands corresponding to the amplified fragments were visualized
on a UV table. Restriction analysis using SpeI (MBI Fermentas)
was performed according to manufacturer’s suggestions and
sequencing was performed using a commercial sequencing service
(SeqLab, Göttingen, Germany).
Thyroglobulin RT-PCR assay sensitivity
RT-PCR assay sensitivity was determined by mixing total RNA
isolated from whole blood of a negative control patient (negative
with normal and high RT-PCR sensitivity) with total RNA isolated
from normal human thyroid tissue in serial dilutions of 1:2, 1:5
and 1:10 steps, respectively. RT-PCR was performed and analysed
Table 1 Oligonucleotides and primers
Oligonucleotide Sequence Size of amplicon Gene Bank accession
Thyroglobulin primer (+) 5¢CCTTGTTTGTCCCTGCTTGT 3¢ 219 U93033
Thyroglobulin primer (–) 5¢GTGGGTAGCATGCTGGAGTT 3¢
GAPDH primer (+) 5¢CGTCTTCACCACCATGGAGA 3¢ 300 M33197
GAPDH primer (–) 5¢CGGCCATCACGCCACAGTTT 3¢1652 J Bojunga et al
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as described above. Assuming that one thyrocyte contains approx-
imately 10 pg total RNA, the lower detection limit of the described
RT-PCR assay was calculated as thyroid cells/ml whole blood.
Tissue specificity of TG-expression
Various human tissues, obtained from open surgery and/or
necropsy were immediately frozen in liquid nitrogen and stored at
–80°C until extracted. 100 mg of each frozen tissue sample was
homogenized in 1 ml Tristar-reagent (AGS, Heidelberg, Germany)
and total RNA was isolated according to suggestions of the manu-
facturer and the final RNA preparation was determined as
described. After addition of 20 units RNase inhibitor (Promega) to
prevent RNA degradation, the aliquots were stored in liquid
nitrogen until use. RNA was extracted from the following tissues
and organs: cerebrum, pituitary gland, palatine tonsil, thyroid,
lung, heart, thymus, lymphatic node (located paratracheally), liver,
gall bladder, spleen, pancreas, oesophagus, stomach, duodenum,
jejunum, ileum, vermiform appendix, colon, kidney, suprarenal
gland, urinary bladder, prostate, seminal vesicle, testes, tongue,
muscle, ovary. In addition, two human thyroid carcinoma cell lines
(B-CPAP and FTC 133) were analysed for TG mRNA expression.
RT-PCR was performed and analysed as described above.
Statistics
Statistical comparisons were done using Sigma-Stat statistical
software (Jandel Scientific, Erkrath, Germany). Contingency
tables were used to assess the association between RT-PCR posi-
tivity rates, research subject category and serum TG levels, respec-
tively. Fisher exact test was used to compare the distributions in
contingency tables that had five or less expected observations in
one or more cells. Chi-square analysis was used to compare the
distributions in contingency tables that had five or more observa-
tions expected in each cell. P < 0.05 was considered significant.
RESULTS
Detection of thyroglobulin transcripts by RT-PCR
After optimization of conditions for reverse transcription and poly-
merase chain reaction we were able to detect thyroglobulin tran-
scripts as the expected 219 bp amplicon in human thyroid tissue by
agarose gel electrophoresis. Restriction enzyme digestion with
SpeI resulted in two restriction fragments of the calculated size
and thus confirmed the restriction site in the amplified fragment. In
addition, the PCR product was sequenced and its identity was
consistent with human thyroglobulin cDNA sequence (Gene bank
accession number U93033). PCR amplification using total RNA
isolated from human thyroid tissue without prior reverse transcrip-
tion was performed as described above. PCR without RT was
unsuccessful in amplifying the products predicted from the cDNA
sequence.
Sensitivity of RT-PCR assay
RT-PCR assay sensitivity was determined using mixed aliquots of
total RNA isolated from human thyroid tissue and lymphocytes of
a negative control patient. Assuming that one thyrocyte contains
10 pg total RNA, we could detect the equivalent of 50–80 thyroid
cells ml–1 blood after 30 cycles of PCR and 10–20 thyroid cells
ml–1 blood after 40 cycles by agarose gel electrophoresis
(Figure 1). Thus, there was a 4- to 5-fold increase in sensitivity
after 40 cycles compared with 30 cycles PCR.
Tissue specificity of TG-mRNA expression
To determine whether thyroglobulin mRNA expression is limited
to and so specific for thyroid tissue, total RNA was extracted from
various human tissues (listed in detail in Table 2) and RT-PCR was
performed and analysed as described before using 30 and 40
cycles respectively. After 30 cycles of PCR, thyroglobulin mRNA
expression was exclusively found in thyroid tissue. However, after
40 cycles of PCR, thyroglobulin mRNA expression was not only
limited to thyroid tissue but also found in the thymus, suprarenal
gland, hypophysis, lung, testis and vermiform appendix. Thus,
thyroglobulin mRNA is a tissue-specific transcript after 30 cycles
of PCR, but it is not after 40 cycles of PCR according to the
described assay conditions.
Evaluation of RT-PCR assay in patients and controls
We evaluated 150 patients with differentiated thyroid cancer (112
papillary, 38 follicular cancers), 137 of them without clinical signs
of current metastasis, 13 with known metastasis, 29 patients with
goitre, 19 patients with Hashimoto thyroiditis, 37 patients with
Graves’ disease, and 50 control patients without clinical signs or a
history of thyroid disease. RT-PCR on all blood samples was
performed using 30 and 40 cycles, respectively. Synthesis of
cDNA was achieved in all cases, as determined by successful
amplification of GAPDH cDNA in each sample.
After 30 cycles of PCR, 63/137 patients (45%) with treated
thyroid cancer and no current metastasis were positive for
thyroglobulin mRNA in the peripheral blood, 9/13 patients
(69.2%) with metastasis, 7/29 patients (24%) with goitre, 5/19
patients (26%) with thyroiditis, 9/37 patients (23.7%) with Graves’
disease, and 9/50 control patients (18%).
After 40 cycles of PCR, 111/137 patients (81%) with treated
thyroid cancer and no current metastasis were positive for
thyroglobulin mRNA in the peripheral blood, 11/13 patients (85%)
with metastasis, 19/29 patients (66%) with goitre, 13/19 patients
(68%) with thyroiditis, 29/37 patients (78%) with Graves’ disease,
and 41/50 control patients (82%). Results are summarized in
Figure 2.
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Figure 1 Thyroglobulin RT-PCR sensitivity assay. Total RNA isolated from
human thyroid tissue was mixed with total RNA from peripheral-blood
mononuclear cells. (A) Sensitivity after 30 cycles of PCR amplification.
By ethidium bromide staining, thyroglobulin mRNA equivalent to
50–80 cells ml–1 blood was visualized. (B) Sensitivity after 40 cycles of PCR
amplification. By ethidium bromide staining, thyroglobulin mRNA equivalent
to 15–20 cells ml–1 blood was visualized. Circulating thyroglobulin mRNA in thyroid cancer 1653
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Serum thyroglobulin values were available on all 150 patients
with thyroid carcinoma and were determined in the serum super-
natant of the cell preparation for total RNA. 137 patients of the
above-mentioned had TG serum levels below 5 ng ml–1 (mean
0.89 ng ml–1 ± 0.075). All 13 patients with metastatic disease had
TG serum levels above 5 ng ml–1 (mean 173 ng ml–1 ± 49.8).
Patients with TG serum levels < 5 ng ml–1 were RT-PCR positive
in 45.9%, and patients with serum levels > 5 ng ml–1 were RT-PCR
positive in 69.2% of cases. Taken together, there was no
significant correlation between serum thyroglobulin levels and
detectable TG-mRNA (P = 0.18, see Table 3).
DISCUSSION
Using RT-PCR technique, we have developed an assay to detect
thyroglobulin mRNA transcripts in the peripheral blood and have
applied this assay to individuals with malignant and non-malig-
nant thyroid disease, as well as to healthy controls. Molecular
detection of tissue-specific gene expression in peripheral blood is
a new diagnostic approach and has been described as a tumour
marker in different solid tumours, such as prostate cancer (Moreno
et al, 1992), neuroblastoma (Mattano et al, 1992), and breast
cancer (Datta et al, 1994). Especially in prostate cancer, detection
of circulating tumour cells could be shown to precede the detec-
tion of secondary disease by serum markers determined by
immunoassays (Ghossein et al, 1995). To date, only three studies
have been published, which have explored blood-borne thyro-
globulin mRNA as a potential tumour marker in thyroid cancer
(Ditkoff et al, 1996; Tallini et al, 1998; Ringel et al, 1998).
Using ‘normal’ RT-PCR sensitivity, PCR results were signifi-
cantly more often positive in patients with thyroid cancer and
metastasis (69%) compared with controls (18%). Interestingly, in
patients with a history of thyroid cancer but no known current
metastasis, PCR results were also significantly more often positive
(46%) compared with controls. To date we cannot determine
whether TG mRNA in these patients is falsely positive or these
patients are not cured and will develop clinically-evident
secondary disease. Therefore, a prospective follow-up study of the
patients with a positive PCR result of TG mRNA expression in
peripheral blood is now performed and this might add further
information to clarify this important issue.
In contrast, frequency of RT-PCR positivity in control patients
did not significantly differ from that in patients with goitre (24%),
Graves’ disease (24%) and patients with Hashimoto thyroiditis
(26%). Interestingly, although they metastasize in a different
manner – haematogen vs lymphogen (Simpson et al, 1987) – there
was no detectable difference in PCR results between patients with
follicular and papillary thyroid cancer, respectively. There was
also no correlation between the status of lymph node involvement
at date of surgery and PCR results. Multiple peripheral blood
samples could be analysed for TG mRNA in two of the patients
with known metastasis. Although TG serum levels were highly
Table 2 Specificity of TG mRNA expression in different human tissues after
30 and 40 cycles of PCR, respectively
Tissue TG mRNA expression
30 cycles  40 cycles
Cerebrum – –
Hypophysis – +
Tongue – –
Palatine tonsil – –
Thyroid + ++
Thymus – +
Lung – +
Heart – –
Lymph node – –
Liver – –
Gall bladder – –
Oesophagus – –
Stomach – –
Duodenum – –
Ileum – –
Appendix – +
Colon – –
Spleen – –
Pancreas – –
Kidney – –
Suprarenal gland – +
Urinary bladder – –
Seminal vesicle – –
Prostate – –
Testes – +
Ovary – –
Muscle – –
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Figure 2 TG mRNA positivity rates in research subjects categories.
(A) controls, (B) patients with a history of thyroid cancer and no known
metastasis, (C) patients with metastasis, (D) patients with thyroiditis,
(E) patients with Graves’ disease, (F) patients with goitre. All experiments
were performed using 30 cycles of PCR amplification and 40 cycles of PCR
amplification, respectively (*P < 0.005 vs control, Chi-square test;
** P < 0.005 vs control, Fisher exact test)
Table 3 Correlation between TG mRNA detection and serum TG values in
patients with and without metastasis (taken together) after 30 cycles of PCR.
Category with a serum thyroglobulin > 5 ng ml–1 includes all 13 patients with
known metastasis. There was no significant correlation between serum
thyroglobulin levels and detectable TG-mRNA (P = 0.18)
RT-PCR positive cases
Cases (n) n %
Serum thyroglobulin > 5 ng ml–1 13 9 69.2
Serum thyroglobulin < 5 ng ml–1 137 63 45.91654 J Bojunga et al
British Journal of Cancer (2000) 82(10), 1650–1655  © 2000 Cancer Research Campaign
increased in both patients, even one negative RT-PCR result was
obtained in both patients. The lack of detectable RT-PCR tran-
scripts is difficult to explain, but on the other hand occurrence of
negative peripheral blood samples in patients with metastatic
disease has been noted in other tumour models, and intermittent
release of tumour cells in the bloodstream may be one possible
explanation (Ghossein and Rosai, 1996).
Although we observed a significant correlation between PCR
positivity and the diagnosis of metastasized thyroid cancer with
the described ‘normal’ assay sensitivity, results completely
changed when applying 40 cycles of PCR instead of 30. Patients in
all groups were positive for thyroglobulin mRNA in the peripheral
blood in 66–85% without any significant difference or correlation
between the single groups.
Until now, the clinical value of this RT-PCR approach could not
definitively be determined and data from recent studies are partly
inconsistent and contradictory (Haber, 1998). The application of
this technique to detect recurrent thyroid cancer was first reported
by Ditkoff et al (1996), who could demonstrate the presence of
thyroglobulin mRNA transcripts in the peripheral blood in 9/9
patients with known metastatic thyroid cancer, 5/22 patients
without current metastasis but a history of treated metastasis, 2/56
patients without current and no history of metastasis and 0/7
control volunteers.
Tallini et al (1998) reported that thyroglobulin mRNA could be
detected in blood by RT-PCR in 4/20 patients with benign nodules,
in 15/24 patients with treated thyroid cancer and 0/11 controls.
However, they could detect TG mRNA in all of these controls as
well as in 10 human cell lines when PCR amplification was
extended from 30 to 40 cycles.
Finally Ringel et al (1998) recently reported an RT-PCR assay to
detect blood-borne thyroglobulin mRNA. Of 14 patients with
known metastasis based on radioscanning, all had detectable
thyroglobulin mRNA in blood compared with 7/35 patients with
negative radioiodine scans. Among 19 patients with residual
radioiodine uptake in the thyroid bed, thyroglobulin mRNA was
detectable in the blood of 12. Their assay was also positive in all
10 control subjects and the authors were able to identify these
cells as putative circulating thyroid cells. Assay sensitivity was
determined to detect 10 cells ml–1 blood.
A variety of technical factors may contribute to the effect of
different results obtained in the cited literature and our study. For
example, different approaches were used to isolate total RNA from
peripheral blood. Ditkoff et al (1996) used ‘RNA-STAT 60’ to
extract total RNA, Tallini and coworkers used a Ficoll-gradient
and Ringel et al extracted total RNA from whole blood with
TRIzol™ reagent. Because of the best results in our hands, we
used a Percoll-gradient to isolate nucleated cells from peripheral
blood, followed by RNA extraction using a commercial extraction
kit, but we were also able to detect thyroglobulin mRNA when
extracting total RNA with TRIzol™ and – unlike Ringel et al –
even when using a Ficoll-gradient.
To determine assay sensitivity, we used a technique comparable
with the one reported by Ringel et al (1998). Initial experiments to
measure assay sensitivity by mixing thyroid cells from human
thyroid carcinoma cell lines (B-CPAP and FTC 133) with lympho-
cytes failed because of the very low level of TG mRNA expression
in these cell lines. This phenomenon of decreased and possibly
undetectable TG mRNA expression in differentiated thyroid
carcinoma has already been described by other investigators
(Hoang-Vu et al, 1992).
Ditkoff et al (1996) also used a human thyroid carcinoma cell
line to determine assay sensitivity, but using unstimulated cells,
only 200 cells ml–1 blood were detectable compared with 20 cells
ml–1 blood when cells were stimulated with TSH. In view of these
results and obvious technical limitation, assay sensitivities may
reflect more approximate estimations than exact values and thus
may be difficult to compare between the single studies.
Nevertheless, we could clearly show a dramatic effect of
different assay sensitivities on the percentage of RT-PCR positive
patients. After 30 PCR amplification cycles we achieved an assay
sensitivity comparable to that reported by Tallini et al (1998) and
in addition obtained similar results concerning TG mRNA posi-
tivity in patients. After 40 PCR amplification cycles we achieved
an assay sensitivity comparable to that reported by Ringel et al
(1998), but in contrast obtained a very high percentage of RT-PCR
positive patients in all groups and thus completely different results
without any significant differences between the groups or
correlation with status of disease.
The reason for this high percentage of RT-PCR positive patients
is unclear. Ringel et al were able to detect TSH-receptor and
TG-positive cells by magnetic cell sorting in two studied control
patients but not in one athyreotic patient and identified these cells
as thyrocytes. In contrast, Tallini et al were able to detect TG
mRNA transcripts in a variety of human cell lines and concluded
that non-specific low level expression of a variety of genes in
different cell types, or illegitimate transcription, may also occur in
peripheral-blood leukocytes.
We favour the latter hypothesis, because after 40 cycles of PCR
amplification, there was no difference in the percentage of positive
PCR results irrespective of the thyroid status of the patients. In addi-
tion, we could also detect TG mRNA transcripts in the peripheral
blood of two patients, who underwent total thyroidectomy due to
medullary thyroid cancer, after 40 cycles but not after 30 cycles of
PCR amplification. Therefore, detection of TG mRNA in peripheral
blood at high assay sensitivities might reflect detection of
illegitimate transcription in cell types of non-thyroid origin – e.g.
lymphocytes – as it has been described earlier (Chelly et al, 1989).
In another set of experiments we tested whether TG mRNA
expression is limited to and so specific for thyroid tissue. Tissue-
specific expression of TG mRNA has not been determined in the
earlier studies of Ditkoff et al (1996), Tallini et al (1998), and
Ringel et al (1998). Although TG mRNA was exclusively
detectable in thyroid tissue after 30 cycles of PCR amplification, it
was also found to be expressed in the thymus, suprarenal gland,
duodenum, lung, testis and appendix after 40 cycles of PCR ampli-
fication. In part, this phenomenon has already been described by
other investigators (Aust et al, 1998). As a consequence, we have
to assume that TG mRNA expression determined by RT-PCR is
specific for thyroid cells using a normal assay sensitivity, but it is
not specific using a high assay sensitivity.
In summary, with a normal RT-PCR sensitivity TG mRNA
transcripts are specific for thyroid tissue and detectable in the
peripheral blood of controls and patients with thyroid disease,
which correlates with a diagnosis of cancer. However, with a high
RT-PCR sensitivity, TG mRNA expression was found not to be
specific for thyroid tissue and in addition was not correlated with a
diagnosis of thyroid cancer. Furthermore, in patients with clini-
cally known metastases there was no additional information of the
PCR result of our assay compared with serum TG levels, which is
part of the current ‘gold standard’ to detect disease recurrence
(Herle and Uller, 1975; Gerfo et al, 1979).Circulating thyroglobulin mRNA in thyroid cancer 1655
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Taken together, the detection of circulating thyroid cancer
micro-metastases in peripheral blood might be a new tool in
clinical research. The high sensitivity of these methods, however,
is combined with a possible decrease in specificity. Therefore,
precaution is necessary to exclude artificial results. A standardiza-
tion of cDNA preparation, gene-specific primer pairs, optimal
RT-PCR conditions and the determination of possible threshold
caused by cells of non-thyroid origin is mandatory to obtain
reliable and comparable results. In view of our data obtained for
sensitivity and specificity, we believe that a clinically useful assay
will require further assay refinement, e.g. quantitative assay to
permit the distinction of weakly and more strongly-positive
RT-PCR results. A number of questions remain to be answered and
further studies are necessary to determine how many of the
patients without known metastasis and normal TG serum levels
but a positive PCR result have or will develop secondary disease.
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